Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
Status:
Terminated
Trial end date:
2020-04-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability, identify a
recommended dose for expansion (RDE) / recommended phase II dose (RP2D), pharmacodynamics,
and antitumor activity of Oregovomab vaccination in combination with Nivolumab as a novel
combinatorial immunotherapeutic strategy in in female patients with recurrent epithelial
ovarian cancer (EOC) who progressed after two or more prior lines of cytotoxic chemotherapy.